In this picture supplied by Eli Lilly, a scientist tests possible COVID-19 antibodies in a lab in Indianapolis, Ind. On Monday, U.S. federal government authorities revealed they are putting an early end to a research study checking an Eli Lilly antibody drug for individuals hospitalized with COVID-19 due to the fact that it is not likely to assist.

The trial studied the effectiveness of bamlanivimab in mix with the antiviral remdesivir on hospitalized COVID-19 clients. Scientist concluded the antibody treatment was “not likely to assist.”

(Image credit: David Morrison/AP)

Read more: